DarioHealth Q2 Revenue Misses by 12%, Pharma Exit Weighs on Top Line
DRIO sits 31% above its 52-week low of $5.845.
Summary
DarioHealth's Q2 revenue fell to $5.2M, missing consensus by 12% and declining year-over-year, driven by the discontinuation of its pharma-related business. Gross margin improved to 62% from 55% due to better product mix and a one-time tariff refund, while operating expenses dropped to $9.7M on cost discipline. The company posted a net loss of $7.9M, slightly better than expected. This follows a $23.5M offering in July that provided a cash lifeline after the 10-Q revealed cash had collapsed to $6.6M. Management expects revenue growth to accelerate by end-2026, with new programs contributing in Q4, but the near-term outlook remains challenged by the ongoing business transition.
At the time of this announcement, DRIO was trading at $7.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75M. The 52-week trading range was $5.84 to $17.74. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.